• Led brand strategy development and tactical execution for multiple acute care, hospital brands within the cardiovascular business unit• Developed and executed conversion strategy for Calcium Channel Blocker (CCB) franchise (CARDENE I.V. and CLEVIPREX) • Co-led cross-functional team to manage supply constraints though the execution of strategic contracting strategy for CCB franchise resulting in the company exceeding financial goals for the year• Evaluated and worked with cross-functional partners to execute private labeling strategy for CARDENE I.V.• Exceeded net revenue goals each year; Percent to goal each year: 2018 = 125%, 2019 = 111%, 2020 = 107%• Relaunched RETAVASE for ST-Elevation Myocardial Infarction (STEMI) after an extended absence from the market following manufacturing challenges• Worked with National Account Management team and Inside Sales to ensure coordination of launch efforts for RETAVASE• Spearheaded project to gain additional investment for RETAVASE, including initial Field Force support, resulting in increased momentum for the bran.• Worked closely with NAM team, Inside Sales, and Hospital Sales Specialists to fully execute brand plan strategy and coordinate tactics for RETAVASE • Rapidly mobilized commercial team planned and executed strategy to capitalize on acute opportunity related to global pandemic in 2020 resulting in significantly increased sales from new accounts, some of which were maintained post the acute opportunity; net revenue increased 1,873%

• Led commercial product life-cycle management, new product planning, and development and maintenance of business cases and financial analysis for pipeline products and new indications• Completed benchmarking analysis to establish New Product Planning functional area within the company including a gap analysis of current capabilities and development of strategic action plan for building out the department

• Led execution of pilot re-launch of ZYFLO CR • Evaluated overall brand strategy, positioning, messaging, and channel strategy for ZYFLO CR and developed the Strategic Business Plan for full re-launch• Managed a 10 territory nationwide contract sales team • Coordinated with cross-functional team members to manage ZYFLO Connect a specialty pharmacies and patient services hub including: reimbursement and financial assistance• Evaluated and managed lifecycle opportunities for the ZYFLO franchise• Uncovered impending launch of generic competition then mobilized company to prepare and execute launch of zileuton AG (authorized generic) concurrent with launch of first generic

• Provide brand planning to small to medium size businesses across numerous verticals

• Mobilized internal and external stakeholders for launch of RUCONEST; Completed launch plan research, development, and execution in 8 months with limited budget and sales were trending to exceed goal • Built and managed HAEA and HAEi ultra-orphan disease patient advocacy group relationships, meeting bi-weekly with senior leadership team, leading to the President and KOL speaking at RUCONEST launch • Launched innovative contest introducing Salix to the HAE community and building database of over 300 patients; Exceeded database goal by 500%• Developed and grew relationships with U.S. HAE “Center of Excellence” KOLs, Dr. Marc Riedl and Dr. Bruce Zuraw; Resulted in securing physician press release quotes, fielding media calls, and participation in Satellite Media Tour • Coordinated with manage markets team and director of reimbursement to establish RUCONEST specialty pharmacies and patient services hub including: reimbursement and financial assistance, nursing care, and product training• Collaborated with Regulatory, Medical Affairs, and Clinical Development teams to support launch and strategic goals• Built and rolled out sales rep training initiatives, patient/caregivers self-administration training, and nurse training/certification programs• As the company’s recognized rare disease expert, spearheaded 1st companywide education on unique commercial intricacies of launching RUCONEST • Completed market assessments to determine whether to pursue RUCONEST for hereditary angioedema or additional indications; Presented recommendations to senior leadership; Recognized as 1 of 4 Salix cornerstone programs • Managed multiple market research projects in preparation for launch including: physician positioning, concept and message testing, competitive analysis, and quantitative patient segmentation

• Established strategy and executed tactical HCP plan to increase the number of injecting accounts for Salix’s 1st medical device, an injectable implant for fecal incontinence; Resulted in 522 procedures in 2012 and 1,916 in 2013 (267%)• Managed market research to determine the value proposition for SOLESTA; Incorporated learning into a value-based selling education and training program for the sales team; Resulted in accelerated product adoption • Developed and rolled out national “best-in-class” physician training program • Created and rolled out on-demand physician training program empowering sales team to train physicians directly; Resulted in rep credibility and individual training cost reduction for 636 physicians from $3750 to $200 in year 1 and $130 in subsequent years; saving the company $2.25M in training costs in 2014• Developed and implemented sales process tool to sell in “buy and bill” environment, improved territory efficiencies and effectiveness

Talecris Biotherapeutics was purchased by Grifols, SA in June 2011• Led commercial product life-cycle management, new product planning, and development and maintenance of business cases and financial analysis for pipeline products and new indications• Managed global brand alignment and efficiencies across US, Canada, and Europe • Led launch team, including 11 subteams, in the U.S. and Canada in the development of commercialization strategy and business case for Prolastin-C Liquid in late-stage development for alpha-1 antitrypsin deficiency, an orphan disease• Commercial lead for Plasmin, a thrombolytic in mid-stage development• Member of US launch team for Prolastin-C; managed translation of clinical data to messages and materials for global markets including: comprehensive monograph, training materials, scientific slide decks, and press releases• Managed KOL Advisory Boards gaining insight on various aspects of brand globally for Pulmonary franchise • Developed and managed global communication plan and global health economics and outcomes research strategy• Served on two global project teams as primary commercial partner to research and development

• Relaunched Thrombate III for hereditary antithrombin deficiency, an orphan disease, in U.S. market, managed global commercial development plan, and conducted market assessments for new indications• Delivered business case reversing decision to discontinue production and exit the market; Resulted in 920% increase in annual company spend and major manufacturing project approval involving high capital expenditures• Achieved sales growth of over 31% in 2007 (volume growth = 17%) and 36% in 2006 (volume growth =34%), without sales force support• Secured partners, built, and led a cross-functional team driving all initiatives around Thrombate III including clinical development, scientific communications, CME activity, KOL development, and promotions• Identified, developed, and maintained national KOL relationships: resulted in multiple clinical initiatives• Built relationships with key distributors and GPO partners elevating Thrombate III brand and driving sales • Partnered with patient advocacy group (NATT) on development, printing, and distribution of treatment guidelines • Served on global project team as primary commercial partner to research and development

Formerly Bayer Biological Products• Conducted primary and secondary research, analyzed and reported results, and made recommendations about strategic direction for specific product lines

• Ranked #1 regionally out of 8 and #2 nationally out of 43 in sales and company growth • Sold 4 biotechnology plasma-based prescription drugs WinRho SDF (ITP), Autoplex T (Hemophilia), Aloprim (Oncology), and Nabi HB (Hepatitis B) to Pediatric and Adult Hem/Onc Physicians, Hepatologists/Liver Transplant

• Ranked #3 in district out of 8, , #15 regionally out of 45, and #72 nationally out of 275 in sales and company growth; Awarded 2 times the District Representative of the Quarter • Sold 4 prescription drugs (Duragesic, Aciphex, Sporonox, and Propulsid) to high prescribing Primary Care Physicians, Neurologists, Anesthesiologists, Rheumatologists, Physiatrists, Dermatologists, and Podiatrists